We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+17.52%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$22.3M
Cap. Flow
+$13.3M
Cap. Flow %
11.44%
Top 10 Hldgs %
63.03%
Holding
49
New
5
Increased
5
Reduced
1
Closed
11

Top Buys

Rank Stock Value
1
BSLK
Bolt Projects Holdings
BSLK
+$3.9M
2
ZLAB icon
Zai Lab
ZLAB
+$3.4M
3
CLYM
Climb Bio
CLYM
+$3.28M
4
SLNO
Soleno Therapeutics
SLNO
+$3.06M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$1.04M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$814K
2
LONA
LeonaBio Inc
LONA
+$477K
3
PACB icon
Pacific Biosciences
PACB
+$376K
4
CABA icon
Cabaletta Bio
CABA
+$353K
5
ROIV icon
Roivant Sciences
ROIV
+$343K

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Materials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$12.4B
$760K 0.65%
10,815
– –
BOLT icon
27
Bolt Biotherapeutics
BOLT
$7.78M
$756K 0.65%
58,348
– –
BCYC
28
Bicycle Therapeutics
BCYC
$292M
$715K 0.62%
31,585
+14,285
+83% +$330K
BSLK
29
DELISTED
Bolt Projects Holdings
BSLK
$666K 0.57%
+40,598
New +$3.9M
KYMR icon
30
Kymera Therapeutics
KYMR
$8.94B
$515K 0.44%
10,875
– –
RVMD icon
31
Revolution Medicines
RVMD
$44B
$331K 0.29%
7,300
– –
SWTX
32
DELISTED
SpringWorks Therapeutics
SWTX
$239K 0.21%
7,450
– –
ARGX icon
33
argenx
ARGX
$54.1B
$233K 0.2%
+430
New +$217K
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$2.55B
$212K 0.18%
+3,820
New +$195K
DBVT
35
DBV Technologies
DBVT
$847M
$130K 0.11%
37,095
– –
AFMD
36
DELISTED
Affimed
AFMD
$125K 0.11%
37,247
– –
JBIO
37
Jade Biosciences
JBIO
$1.34B
$100K 0.09%
1,370
– –
ALXO icon
38
ALX Oncology
ALXO
$290M
$76.3K 0.07%
41,950
– –
ABCL icon
39
AbCellera Biologics
ABCL
$2.12B
– –
-50,971
Closed -$151K
LONA
40
LeonaBio Inc
LONA
$72.1M
– –
-18,000
Closed -$477K
BMEA icon
41
Biomea Fusion
BMEA
$91.3M
– –
-40,000
Closed -$180K
CABA icon
42
Cabaletta Bio
CABA
$455M
– –
-47,150
Closed -$353K
KYNB
43
Kyntra Bio
KYNB
$29.4M
– –
-2,484
Closed -$55.4K
IMCR icon
44
Immunocore
IMCR
$1.73B
– –
-6,750
Closed -$229K
IMTX icon
45
Immatics
IMTX
$1.32B
– –
-15,700
Closed -$182K
KOD icon
46
Kodiak Sciences
KOD
$2.84B
– –
-31,922
Closed -$75K
PACB icon
47
Pacific Biosciences
PACB
$370M
– –
-274,488
Closed -$376K
ROIV icon
48
Roivant Sciences
ROIV
$26.2B
– –
-32,470
Closed -$343K
GRAL
49
GRAIL Inc
GRAL
$3.1B
– –
-19,866
Closed -$305K
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q3 2024 Portfolio in Review

As of Q3 2024, Nan Fung Group Holdings held 49 positions worth $116M, up 24% from $93.7M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Nan Fung Group Holdings deployed $13.3M of net new capital in Q3 2024, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Bolt Projects Holdings: 40,598 shares worth $666K.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was KalVista Pharmaceuticals, an estimated $814K trimmed.

  • Nan Fung Group Holdings's largest Q3 2024 buy was Bolt Projects Holdings: 40,598 shares worth $666K.
  • Nan Fung Group Holdings added most to Zai Lab in Q3 2024, an estimated $3.4M increase.
  • Nan Fung Group Holdings's biggest Q3 2024 reduction was KalVista Pharmaceuticals, cutting an estimated $814K.
  • Nan Fung Group Holdings fully exited LeonaBio Inc in Q3 2024, selling an estimated $477K.
  • Nan Fung Group Holdings's ten largest holdings make up 63% of its $116M portfolio in Q3 2024.
  • Nan Fung Group Holdings opened 5 new positions and closed 11 in Q3 2024.
  • Nan Fung Group Holdings's portfolio value rose 24% quarter-over-quarter to $116M.

Based on Nan Fung Group Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.